Active research focuses on new antibody-drug conjugates such as disitamab vedotin in HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-expressing tumours, sacituzumab tirumotecan in HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-negative disease, and sigvotatug vedotin in solid tumours. Phase 3 studies are evaluating capivasertib combined with a CDK4/6 inhibitor plus fulvestrant, tucatinib with trastuzumab and pertuzumab in HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive metastatic cancer, and lasofoxifene combined with abemaciclib. Earlier-phase trials are testing oral selective estrogen receptor degraders, the phosphatidylinositol-3-kinase alpha (PI3K-alpha) inhibitor inavolisib, and autologous T-cell receptor therapies targeting patient-specific neoantigens. Several studies are pairing durvalumab or pembrolizumab with HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-directed therapy, and one phase 2 trial combines a fasting-mimicking diet with chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → and toripalimab in TNBC. Imaging research includes dedicated breast positron emission tomography and fluoroestradiol positron emission tomography to predict endocrine response.
Where the evidence stands
For HR+/HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-negative metastatic disease the evidence base is deep: multiple phase 3 studies of CDK4/6 inhibitors and newer agents like capivasertib have reached regulatory approval. HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-directed antibody-drug conjugates are similarly mature. At the frontier, promising agents such as disitamab vedotin, sevabertinib, and oral selective estrogen receptor degraders sit in phase 1 or 2 trials and require larger confirmatory studies. Cell therapies and oncolytic viruses in TNBC are early phase 1 investigations. Dietary and behavioural interventions, while encouraging, are being tested in small phase 2 settings.
What this means for people affected
Breast cancer is one of the most therapeutically diverse cancers, with distinct paths depending on receptor status and genetic background. The field is fast-moving, and people with HR+ or HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive disease now have several lines of targeted therapyDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → that were not available a decade ago. Triple-negative disease has historically had fewer options, but immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → and antibody-drug conjugates are expanding what is possible. Genetic testing, including for BRCAGenes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation → and PIK3CA, increasingly determines which treatments are offered.
Last updated April 22, 2026
Recent research findings
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
✦ Significant findingA meaningful signal from later-stage research, or a strong phase 2 result that stands out from routine findings.Meta-AnalysisStatistical pooling of results from multiple studies.Published: April 21, 2026
Acupuncture for Breast Cancer Nausea Relief
Researchers are studying whether acupuncture can help reduce nausea and vomiting in breast cancer patients undergoing chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →. They will analyze data from multiple studies to understand which acupuncture methods are most effective. The results will help clinicians choose the best acupuncture options for their patients.
Why it matters: This research aims to provide more evidence-based options for clinicians to treat chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →-induced nausea and vomiting in breast cancer patients.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 21, 2026
ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → dose intensity and neutropenia in early breast cancer
Researchers studied how chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → dose intensity affects outcomes in early breast cancer patients. They found that patients who received reduced chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → dose intensity without neutropenia had poorer outcomes, but those with neutropenia showed no significant difference in survival. These findings are preliminary and require further confirmation.
Why it matters: This study's findings may help guide treatment decisions for early breast cancer patients.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 21, 2026
New Cancer Research Tool Shows Promise in Predicting Breast Cancer Outcomes
Researchers compared different methods for predicting breast cancer survival using data from over 780 patients. They found that some newer methods were better at predicting survival than older methods. However, the results are based on a single study and need further validation.
Why it matters: This finding could help doctors better understand breast cancer and make more accurate predictions about patient outcomes.
PreclinicalLab or cell studies. No human data yet.Est. completion: July 31, 2026
Mindfulness Intervention for Nutrition in Breast Cancer Survivors
This trial is studying a mindfulness intervention to improve nutrition in women who have survived stage I-III breast cancer. The trial is currently active and not recruiting participants. The goal is to understand the effectiveness of this approach.
Why it matters: This trial aims to help breast cancer survivors make healthier food choices, which can be important for their overall health and well-being.
ReviewSummary and analysis of existing published studies.Published: April 20, 2026
AI Helps Diagnose Breast Cancer-Related Lymphedema
Researchers looked at how artificial intelligence can help diagnose and predict breast cancer-related lymphedema. They found that AI models using different types of data were able to accurately predict lymphedema in some cases. However, more research is needed to confirm these findings.
Why it matters: This study could lead to better diagnosis and treatment of breast cancer-related lymphedema, which can significantly impact the well-being of survivors.
Efficacy
Risk prediction models achieved accuracy rates of 81% to 93.75%, with sensitivity of 95.65%, specificity of 91.03%, and Area Under the Curve (AUC) of 0.751.
PreclinicalLab or cell studies. No human data yet.Est. completion: April 30, 2028
Negative Pressure Wound Therapy for Abdominal Incisions in Obese Breast Reconstruction Patients
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the effectiveness of negative pressure wound therapy in healing abdominal incisions for obese patients undergoing breast reconstruction surgery. The trial is currently recruiting participants. The results of this trial are not yet available.
Why it matters: This trial may help improve wound healing outcomes for obese patients undergoing breast reconstruction surgery.
Recruiting status, early stage trial with no specified phase
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 20, 2026
Managing Breast Cancer in People with Neurofibromatosis Type 1
Researchers reported a case of a woman with neurofibromatosis type 1 who developed triple-negative breast cancer. She underwent surgery, chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →, and reconstruction, and remained disease-free after more than 3 years. The case highlights the challenges of treating breast cancer in people with NF1.
Why it matters: This case emphasizes the importance of individualized care for people with NF1 who develop breast cancer.
✦ Significant findingA meaningful signal from later-stage research, or a strong phase 2 result that stands out from routine findings.Phase 3 TrialLarge controlled trial comparing treatments. The strongest level of trial evidence.Published: April 20, 2026
New Cancer Treatment's Cost-Effectiveness Questioned
Researchers analyzed the cost-effectiveness of a new cancer treatment called capivasertib plus fulvestrant for patients with a specific type of breast cancer. They found that while this treatment provided more quality of life and longer survival, it was not cost-effective at its current price. The cost of the treatment had a significant impact on its cost-effectiveness.
Why it matters: This finding has implications for how this treatment is covered by insurance and made available to patients.
Efficacy
Capivasertib plus fulvestrant yielded more quality-adjusted life-years (1.89 vs. 1.29) and life years (3.31 vs. 2.49) than fulvestrant alone.
Extrapolation of survival data reflects limited long-term trial data and increases uncertainty surrounding model parameters.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 20, 2026
New Study Explores Benefits of Specialized Breast Cancer Imaging
Researchers used a specialized imaging test called dbPET to examine breast cancer patients before surgery. They found that certain factors, such as a protein called Ki-67, were strongly associated with the test's results. However, it's unclear whether the test's results should be compared to healthy breast tissue.
Why it matters: This study may help doctors determine which patients would benefit most from this specialized imaging test.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 20, 2026
New Cancer Treatment Shows Promise in Lab Experiments
Researchers tested a new treatment called PEPD on breast cancer cells that are resistant to current treatments. They found that PEPD can eliminate a protein called p95HER2, which is linked to aggressive tumor growth. In lab experiments, PEPD was more effective than other treatments in stopping the growth of these cancer cells.
Why it matters: This finding could lead to new treatment options for patients with HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive breast cancer who are resistant to current therapies.
Efficacy
PEPD achieved complete and lasting tumor elimination in an orthotopic PDX of HER2-positive BC expressing p95HER2.
This study was conducted in lab experiments and has not yet been tested in humans.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 20, 2026
Cancer Navigation Intervention for Breast Cancer Survivors in Rural Areas
Researchers in Canada are testing a cancer navigation intervention for newly diagnosed breast cancer survivors in rural areas. The intervention includes professional navigators who provide support and connect patients with resources. An early study suggests that this intervention may improve quality of life and functional outcomes.
Why it matters: This study aims to address cancer inequities among vulnerable populations in rural areas by evaluating the effectiveness of a cancer navigation intervention.
Phase 1 TrialFirst-in-human trial. Focuses on safety and dosing in small groups.Est. completion: April 30, 2028
Assessing Tumor Response to ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in Triple Negative Breast Cancer
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying how well chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → works in patients with triple negative breast cancer. Researchers are using imaging tests and laboratory analysis to assess tumor response. The trial is currently active but not recruiting participants.
Why it matters: This trial aims to improve our understanding of how to effectively treat triple negative breast cancer.
DCE-MRI and MBI in Assessing Tumor Response to ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in Patients With Triple Negative Breast Cancer
A Study of Disitamab Vedotin in Adults With HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation → Expressing Advanced Breast Cancer
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine TherapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation →
Targeted TherapyDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
